PURPOSE: Asparaginase is an essential component of pediatric acute lymphoblastic leukemia (ALL) therapy. However, asparaginase-induced hypersensitivity reactions can compromise its efficacy either by directly influencing the pharmacokinetics of asparaginase or by leading to a discontinuation of asparaginase treatment. Here, we report successful challenges using native Escherichia coli asparaginase after previous hypersensitivity reactions to both PEGylated E. coli asparaginase and Erwinia asparaginase. PATIENTS AND METHODS: The two patients included in this case report were diagnosed with B-precursor ALL at St. Jude Children's Research Hospital and were treated with a common regimen. Both patients developed hypersensitivity reactions to PEGylated E. coli asparaginase and Erwinia asparaginase early in treatment, and they were challenged with native E. coli asparaginase. Serum samples were collected for estimating the pharmacokinetic parameters of each patient during native E. coli asparaginase therapy. RESULTS: Challenges with native E. coli asparaginase were successful, and asparaginase serum concentrations above therapeutic levels were attained in both patients. CONCLUSIONS: These two cases suggest that some patients can be given native E. coli asparaginase after hypersensitivity reactions to PEGylated asparaginase and achieve therapeutic concentrations of the drug in serum.
PURPOSE:Asparaginase is an essential component of pediatric acute lymphoblastic leukemia (ALL) therapy. However, asparaginase-induced hypersensitivity reactions can compromise its efficacy either by directly influencing the pharmacokinetics of asparaginase or by leading to a discontinuation of asparaginase treatment. Here, we report successful challenges using native Escherichia coliasparaginase after previous hypersensitivity reactions to both PEGylated E. coli asparaginase and Erwinia asparaginase. PATIENTS AND METHODS: The two patients included in this case report were diagnosed with B-precursor ALL at St. Jude Children's Research Hospital and were treated with a common regimen. Both patients developed hypersensitivity reactions to PEGylated E. coli asparaginase and Erwinia asparaginase early in treatment, and they were challenged with native E. coliasparaginase. Serum samples were collected for estimating the pharmacokinetic parameters of each patient during native E. coliasparaginase therapy. RESULTS: Challenges with native E. coliasparaginase were successful, and asparaginase serum concentrations above therapeutic levels were attained in both patients. CONCLUSIONS: These two cases suggest that some patients can be given native E. coliasparaginase after hypersensitivity reactions to PEGylated asparaginase and achieve therapeutic concentrations of the drug in serum.
Authors: M A Schorin; S Blattner; R D Gelber; N J Tarbell; M Donnelly; V Dalton; H J Cohen; S E Sallan Journal: J Clin Oncol Date: 1994-04 Impact factor: 44.544
Authors: M H Woo; L J Hak; M C Storm; W E Evans; J T Sandlund; G K Rivera; B Wang; C H Pui; M V Relling Journal: Leukemia Date: 1998-10 Impact factor: 11.528
Authors: Daniel Y Joh; Zackary Zimmers; Manav Avlani; Jacob T Heggestad; Hakan B Aydin; Nancy Ganson; Shourya Kumar; Cassio M Fontes; Rohan K Achar; Michael S Hershfield; Angus M Hucknall; Ashutosh Chilkoti Journal: Adv Healthc Mater Date: 2019-03-25 Impact factor: 9.933
Authors: Yiwei Liu; Colton A Smith; John C Panetta; Wenjian Yang; Lauren E Thompson; Jacob P Counts; Alejandro R Molinelli; Deqing Pei; Nancy M Kornegay; Kristine R Crews; Hope Swanson; Cheng Cheng; Seth E Karol; William E Evans; Hiroto Inaba; Ching-Hon Pui; Sima Jeha; Mary V Relling Journal: J Clin Oncol Date: 2019-06-12 Impact factor: 44.544
Authors: Cosby A Stone; Yiwei Liu; Mary V Relling; Matthew S Krantz; Amanda L Pratt; Andrew Abreo; Jonathan A Hemler; Elizabeth J Phillips Journal: J Allergy Clin Immunol Pract Date: 2018-12-14
Authors: Christian A Fernandez; Colton Smith; Wenjian Yang; Charles G Mullighan; Chunxu Qu; Eric Larsen; W Paul Bowman; Chengcheng Liu; Laura B Ramsey; Tamara Chang; Seth E Karol; Mignon L Loh; Elizabeth A Raetz; Naomi J Winick; Stephen P Hunger; William L Carroll; Sima Jeha; Ching-Hon Pui; William E Evans; Meenakshi Devidas; Mary V Relling Journal: Blood Date: 2015-05-18 Impact factor: 22.113
Authors: Christian A Fernandez; Colton Smith; Seth E Karol; Laura B Ramsey; Chengcheng Liu; Ching-Hon Pui; Sima Jeha; William E Evans; Fred D Finkelman; Mary V Relling Journal: J Pharmacol Exp Ther Date: 2015-01-08 Impact factor: 4.030
Authors: Saleh A Mohamed; Mohamed F Elshal; Taha A Kumosani; Alia M Aldahlawi; Tasneem A Basbrain; Fauziah A Alshehri; Hani Choudhry Journal: Int J Environ Res Public Health Date: 2016-10-14 Impact factor: 3.390